Amgen Scores with New Thyroid Eye Disease Formulation

Why It Matters

A more patient‑friendly injection could expand Tepezza’s addressable market and protect Amgen’s revenue against emerging competitors. This shift reflects a broader industry trend toward at‑home biologic therapies, enhancing patient adherence and market penetration.

Key Takeaways

• Subcutaneous Tepezza matches IV efficacy in phase 3
• Twice‑weekly injections replace three‑week IV infusions
• 77% proptosis response vs 20% placebo
• Similar safety profile, mild injection‑site reactions
• Expands market, counters emerging IGF‑1 competitors

Pulse Analysis

9 billion in revenue last year. The drug’s intravenous administration every three weeks, however, has limited broader uptake because of infusion‑center logistics and occasional supply constraints. Recognizing these barriers, Amgen invested in a subcutaneous formulation that can be delivered twice weekly via a wearable on‑body injector, a move aimed at improving patient convenience and sustaining growth in a niche but lucrative market. The subcutaneous option also aligns with broader industry trends toward at‑home biologic administration, which has accelerated after the pandemic.

2 mm reduction in eye bulging—metrics the company says mirror the intravenous benchmark. Safety remained comparable, with only mild-to-moderate injection‑site reactions that did not trigger discontinuations. By offering a twice‑weekly at‑home injection, Amgen removes the need for patients to travel to infusion centers, potentially widening the eligible patient pool and reinforcing adherence.

Amgen’s move comes as several challengers prepare to enter the TED space. Viridian Therapeutics is pursuing two IGF‑1 inhibitors—veligrotug, slated for an FDA decision by June 30, and elegrobart, a subcutaneous autoinjector expected to file in early 2027. Meanwhile, Immunovant’s FcRn blocker batoclimab recently failed a phase 3 study, and Sling Therapeutics is advancing the small‑molecule linsitinib toward phase 3. By securing a patient‑friendly delivery platform now, Amgen not only protects its revenue stream but also positions Tepezza as the de‑facto standard, forcing rivals to differentiate on efficacy or convenience.